Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Gracell Biotechnologies Inc. GRCL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • CN • USD

SharesGrow Score
26/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$6.00
-41.5%

Gracell Biotechnologies Inc. (GRCL) is a Biotechnology company in the Healthcare sector, currently trading at $10.25. It has a SharesGrow Score of 25/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Analyst consensus target is GRCL = $6 (-41.5% upside).

Net income is $608M (loss), growing at -72%/yr. Net profit margin is 0% (thin). Gross margin is 100% (+0 pp trend).

Balance sheet: total debt is $183M against $1.4B equity (Debt-to-Equity (D/E) ratio 0.13, conservative). Current ratio is 6.78 (strong liquidity). Debt-to-assets is 11%. Total assets: $1.7B.

Analyst outlook: 3 / 8 analysts rate GRCL as buy (38%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 10/100 (Fail), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 46/100 (Partial), Future 16/100 (Fail), Income ?/100 (Fail).

$6.00
▼ 41.46% Downside
Average Price Target
The 12-month price target for Gracell Biotechnologies Inc. is $6.00.

GRCL SharesGrow Score Overview

31/100
SharesGrow Score
Below average — proceed with caution
View full scorecard →
VALUE 10/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 16/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GRCL

✗
VALUE Fail
10/100
GRCL trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $6, implying -41.5% from the current price $10. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
GRCL: -100%/yr revenue is, -72%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
~
HEALTH Partial
67/100
Balance sheet GRCL: Debt-to-Equity (D/E) ratio 0.13 (conservative), Current ratio is 6.78 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
GRCL: Gross margin is 100% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
16/100
Analyst outlook: 3 / 8 analysts rate GRCL as buy (38%). Analyst consensus target is $6 (-41.5% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range1.4-10.435
Volume6.37M
Avg Volume (30D)1.46M
Market Cap$197.97M
Beta (1Y)-0.35
Share Statistics
EPS (TTM)-28.25
Shares Outstanding$21.5M
IPO Date2021-01-08
Employees314
CEOWei Cao BM,
Financial Highlights & Ratios
EBITDA$-592.58M
Net Income$-607.51M
Operating Income$-624.66M
Total Cash$1.46B
Total Debt$182.98M
Net Debt$-1.27B
Total Assets$1.66B
Price / Earnings (P/E)-0.4
Analyst Forecast
1Y Price Target$6.00
Target High$6.00
Target Low$6.00
Upside-41.5%
Rating ConsensusHold
Analysts Covering8
Buy 38% Hold 63% Sell 0%
Company Info
CountryCN
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS38406L1035

Price Chart

Track all markets on TradingView
GRCL
Gracell Biotechnologies Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
1.40 52WK RANGE 10.44

People Also View

BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 ERAS
ERAS
Erasca, Inc.
$17.85
+9.44%
 TERN
TERN
Terns Pharmaceuticals, Inc.
$52.68
+0.13%
 DAWN
DAWN
Day One Biopharmaceuticals, Inc.
$21.46
-0.14%
 AMLX
AMLX
Amylyx Pharmaceuticals, Inc.
$16.92
+2.73%
 GLUE
GLUE
Monte Rosa Therapeutics, Inc.
$17.50
-0.28%
 DSGN
DSGN
Design Therapeutics, Inc.
$12.64
+2.35%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message